Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Alkermes is a commercial-stage biopharmaceutical company specializing in CNS (central nervous system) therapeutics, with a portfolio anchored by long-acting injectable antipsychotics (ARISTADA, VIVITROL) and oral oncology products (LYBALVI). The company operates manufacturing facilities in Ohio and Ireland, generating revenue through proprietary products and royalty streams from partnered assets. Despite strong gross margins exceeding 84%, the business faces headwinds from mature product lifecycles and competitive pressure in schizophrenia/addiction treatment markets.
Alkermes monetizes proprietary long-acting injectable (LAI) drug delivery technology through direct commercialization of branded CNS products and manufacturing/royalty agreements. Pricing power derives from differentiated extended-release formulations that improve patient compliance versus daily oral medications, commanding premium pricing in psychiatry markets. The company captures value through high-margin manufacturing (84% gross margin) while partnering with larger pharma for global distribution. Revenue concentration in mature antipsychotic markets limits growth, but minimal variable costs create strong incremental margins on volume expansion.
ARISTADA franchise volume trends and market share versus competing LAIs (INVEGA SUSTENNA, ABILIFY MAINTENA)
LYBALVI commercial uptake and formulary access in competitive atypical antipsychotic market
Pipeline readouts for orexin platform (narcolepsy indication) and next-generation CNS assets
Royalty stream stability from J&J partnership (INVEGA franchise) amid biosimilar threats
Capital allocation decisions including share buybacks and business development activity
Patent cliffs and biosimilar/generic erosion for mature LAI portfolio, particularly ARISTADA facing competition from established INVEGA franchise and potential future generics
Pricing pressure from PBM formulary restrictions, Medicaid rebate expansion, and potential federal drug pricing reform targeting specialty pharmaceuticals
Shift toward oral antipsychotics and digital therapeutics reducing long-term demand for injectable delivery systems
Dominant market position of J&J's INVEGA SUSTENNA/TRINZA franchise in LAI schizophrenia market limits ARISTADA growth potential
Crowded atypical antipsychotic market with multiple branded competitors (VRAYLAR, CAPLYTA, REXULTI) and generic alternatives pressuring LYBALVI uptake
Limited pipeline differentiation versus larger CNS-focused competitors with deeper R&D resources and broader portfolios
Declining revenue trajectory (-6.4% YoY) threatens cash flow sustainability if mature products erode faster than pipeline assets commercialize
Concentration risk in CNS therapeutic area exposes company to regulatory changes or safety concerns affecting entire antipsychotic drug class
low - Pharmaceutical demand for chronic CNS conditions (schizophrenia, addiction disorders) remains relatively stable through economic cycles as patients require continuous treatment regardless of GDP fluctuations. However, Medicaid reimbursement pressures during state budget constraints and commercial insurance formulary restrictions during recessions can modestly impact volume and pricing. The 3.67x current ratio and minimal debt provide financial stability through downturns.
Rising interest rates have minimal direct operational impact given negligible debt (0.04 D/E ratio) and no significant refinancing risk. However, higher rates compress valuation multiples for biotech stocks as investors demand higher equity risk premiums and shift capital toward fixed income. The company's $0.4B free cash flow provides flexibility to return capital during rate volatility. Rate increases also elevate discount rates applied to pipeline assets, potentially reducing M&A valuations for business development opportunities.
Minimal - Alkermes operates with fortress balance sheet (3.67x current ratio, 0.04 D/E) and generates positive free cash flow, eliminating refinancing risk. Credit conditions affect customer base indirectly through hospital/pharmacy working capital and insurance reimbursement cycles, but impact is negligible given stable demand for chronic CNS medications. Tightening credit could delay M&A opportunities or partnership deals but does not threaten core operations.
value - The stock trades at reasonable valuation multiples (3.5x P/S, 10.9x EV/EBITDA) relative to biotech peers, with strong free cash flow generation (7.7% FCF yield) and minimal debt attracting value-oriented investors seeking stable cash flows. Limited growth prospects (-6.4% revenue decline) and mature product portfolio deter growth investors. The combination of profitability, cash generation, and modest valuation appeals to investors seeking pharmaceutical cash flow stories rather than high-risk pipeline bets.
moderate - Biotech stocks typically exhibit elevated volatility, but Alkermes' commercial-stage profile with established revenue base and profitability reduces volatility versus clinical-stage peers. Stock moves primarily on quarterly earnings surprises, pipeline updates, and sector-wide pharmaceutical policy developments rather than binary clinical trial outcomes. The -10.6% one-year return versus +14.2% six-month return indicates episodic volatility around company-specific catalysts.
